Analysis of HIV/AIDS drug resistance mutations in Wuxi City from 2014 to 2016

CHEN Jian-shuang; YIN Yue-qi; CHENG Hao; ZHANG Xuan; YUAN De-fu; ZHANG Xiao-xuan; WANG Xiao-min; WEI Qian-kun; WANG Bei

doi:10.16462/j.cnki.zhjbkz.2021.06.016

Volume 25 Issue 6

Jul. 2021

Turn off MathJax

Article Contents

Article Navigation > CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION > 2021 > 25(6): 709-715

CHEN Jian-shuang, YIN Yue-qi, CHENG Hao, ZHANG Xuan, YUAN De-fu, ZHANG Xiao-xuan, WANG Xiao-min, WEI Qian-kun, WANG Bei. Analysis of HIV/AIDS drug resistance mutations in Wuxi City from 2014 to 2016[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(6): 709-715. doi: 10.16462/j.cnki.zhjbkz.2021.06.016

Citation:

CHEN Jian-shuang, YIN Yue-qi, CHENG Hao, ZHANG Xuan, YUAN De-fu, ZHANG Xiao-xuan, WANG Xiao-min, WEI Qian-kun, WANG Bei. Analysis of HIV/AIDS drug resistance mutations in Wuxi City from 2014 to 2016[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(6): 709-715. doi: 10.16462/j.cnki.zhjbkz.2021.06.016

Citation:

CHEN Jian-shuang, YIN Yue-qi, CHENG Hao, ZHANG Xuan, YUAN De-fu, ZHANG Xiao-xuan, WANG Xiao-min, WEI Qian-kun, WANG Bei. Analysis of HIV/AIDS drug resistance mutations in Wuxi City from 2014 to 2016[J]. CHINESE JOURNAL OF DISEASE CONTROL & PREVENTION, 2021, 25(6): 709-715. doi: 10.16462/j.cnki.zhjbkz.2021.06.016

PDF( 935 KB)

Analysis of HIV/AIDS drug resistance mutations in Wuxi City from 2014 to 2016

doi: 10.16462/j.cnki.zhjbkz.2021.06.016

1.
Department of Epidemiology and Health Statistics, School of Public Health, Southeast University, Nanjing 210009, China
2.
Department of Acute Infectious Diseases Prevention and Control, Xinwu District Center for Disease Prevention and Control, Wuxi 214028, China
3.
Department of Disease Control, Wuxi Center for Disease Prevention and Control, Wuxi 214000, China

Funds:

Jiangsu Postgraduate Scientific Research and Practice Innovation Program KYCX17_0184

Molecular network analysis and social network exploration of HIV-1 infection among young students in Jiangsu Province 0701-184160070478

More Information

Corresponding author: WANG Bei, E-mail: wangbeilxb@163.com
Received Date: 2020-11-11
Rev Recd Date: 2021-01-07
Publish Date: 2021-06-10

Abstract

Abstract

Objective To investigate the characteristics of HIV gene drug resistance changes among human immunodeficiency virus infected person /acquired immune deficiency syndrome patients (HIV/AIDS) in Wuxi City, Jiangsu Province from 2014 to 2016. Methods The HIV/ AIDS population in Wuxi City in 2014 was used as the research object to carry out HIV molecular epidemiological investigation and follow-up research. Basic information of the infected persons were collected, and DNA was extracted from their blood samples. The pol gene fragment was amplified by nest-PCR and sequenced. The sequence was then submitted to the HIV drug resistance database for drug resistance mutation analysis. In 2016, the same population was followed up. The HIV-1 drug resistance mutation was tested again, and the change of drug resistance during two years was analyzed. Results A total of 612 HIV/AIDS cases from 2014 to 2016 were collected. Most of them were aged 30 or above, accounting for 85.46% (523/612), among which the proportion of people aged 50 or older was higher, accounting for 37.25% (228/612). The main route of transmission was homosexual transmission, accounting for 49.67% (304/612). A total of 1 224 samples were tested and 811 pol sequences were successfully obtained. The total resistance rate was 10.11% (82/811). The drug resistance rates to non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors and protease inhibitors were 7.77% (63/ 811), 5.30% (43 /811) and 1.23% (10/811), respectively. The most common mutations were K103N/S and M184V/I. A total of 38 cases of HIV/AIDS had changes in drug resistance before and after follow-up. Conclusion The drug resistance of human immunodeficiency virus-1 (HIV-1) gene level of HIV/AIDS patients in Wuxi was diverse and complex, and the drug resistance changed greatly. Therefore, the monitoring of drug-resistant mutations and the management of antiviral treatment should be strengthened.
- HIV infected person,
- AIDS patients,
- Drug resistance variation

FullText(HTML)

References(19)

References

[1]	Guan X, Han M, Li ZJ, et al. HIV-1 genetic diversity and transmitted drug resistance among newly diagnosed HIV-1 individuals in Jiangmen[J/OL]. (2020-03-01)[2020-10-20]. https://doi.org/10.1002/jmv.25741.
[2]	Yang ZJ, Wei SG, Liu JJ, et al. Characterization of HIV-1 subtypes and drug resistance mutations in Henan Province, China (2017-2019)[J]. Arch Virol, 2020, 165(6): 1453-1461. DOI: 10.1007/s00705-020-04606-6.
[3]	Han XS, Jemal A, Hulland E, et al. HIV infection and survival of lymphoma patients in the era of highly active antiretroviral therapy[J]. Cancer Epidemiol Biomarkers Prev, 2017, 26(3): 303-311. DOI: 10.1158/1055-9965.EPI-16-0595.
[4]	Phillips AN, Cambiano V, Miners A, et al. Effectiveness and cost-effectiveness of potential responses to future high levels of transmitted HIV drug resistance in antiretroviral drug-naive populations beginning treatment: modelling study and economic analysis[J]. Lancet HIV, 2014, 1(2): e85-e93. DOI: 10.1016/S2352-3018(14)70021-9.
[5]	Lakhikumar SA, Ramsing ST, Ranjana DK, et al. Prevalence of drug resistance associated mutations among the anti retroviral therapy exposed HIV-1 infected individuals in Manipur, Northeast India[J]. Curr HIV Res, 2016, 14(4): 360-370. DOI: 10.2174/1570162x14666160401131426.
[6]	Schultze A, Phillips AN, Paredes R, et al. HIV resistance testing and detected drug resistance in Europe[J]. AIDS, 2015, 29(11): 1379-1389. DOI: 10.1097/QAD.0000000000000708.
[7]	Wu J, Norris J, Liu HX, et al. The prevalence of HIV drug resistance among treatment-failure individuals and treatment-naive individuals in China: a meta-analysis[J]. Biomed Environ Sci, 2014, 27(11): 858-871. DOI: 10.3967/bes2014.123.
[8]	Baxter JD, Dunn D, White E, et al. Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial[J]. HIV Med, 2015, 16 Suppl 1(1): 77-87. DOI: 10.1111/hiv.12236.
[9]	袁瑞, 成浩, 陈璐斯, 等. 无锡市HIV-1毒株耐药基因突变的调查研究[J]. 中华疾病控制杂志, 2016, 20(12): 1216-1220. DOI: 10.16462/j.cnki.zhjbkz.2016.12.008. Yuan R, Cheng H, Chen LS, et al. A survey on drug-resistance gene mutations in HIV-1 strains in Wuxi City[J]. Chin J Dis Control Prev, 2016, 20(12): 1216-1220. DOI: 10.16462/j.cnki.zhjbkz.2016.12.008.
[10]	Gartner MJ, Roche M, Churchill MJ, et al. Understanding the mechanisms driving the spread of subtype C HIV-1[J]. EBioMedicine, 2020, 53: 102682. DOI: 10.1016/j.ebiom.2020.102682.
[11]	殷玥琪, 陈剑双, 成浩, 等. 无锡市2013-2016年HIV-1亚型及进化分析[J]. 中华流行病学杂志, 2020, 41(2): 244-245. DOI: 10.3760/cma.j.issn.0254-6450.2020.02.019. Yin YQ, Chen JS, Cheng H, et al. Transition and evolution of HIV-1 subtype among HIV-1 infections in Wuxi City, 2013-2016[J]. Chin J Epidemiol, 2020, 41(2): 244-245. DOI: 10.3760/cma.j.issn.0254-6450.2020.02.019.
[12]	Yin YQ, Liu YX, Zhu J, et al. The prevalence, temporal trends, and geographical distribution of HIV-1 subtypes among men who have sex with men in China: a systematic review and meta-analysis[J]. Epidemiol Infect, 2019, 147(2): e83. DOI: 10.1017/S0950268818003400.
[13]	李梅, 李俊刚, 罗福龙, 等. 重庆市2014年至2018年人类免疫缺陷病毒1型感染者的耐药突变分析[J]. 中华传染病杂志, 2020, 38(5): 283-287. DOI: 10.3760/cma.j.cn311365-20191010-00322. Li M, Li JG, Luo FL, et al. Analysis of drug-resistant mutations in human immunodeficiency virus-1 infected patients in Chongqing City from 2014 to 2018[J]. Chin J Infect Dis, 2020, 38(5): 283-287. DOI: 10.3760/cma.j.cn311365-20191010-00322.
[14]	殷玥琪, 朱靖, 吴楠楠, 等. 中国MSM人群中HIV-1亚型与不同位点耐药突变发生频率的Meta分析[J]. 中华疾病控制杂志, 2017, 21(6): 622-626. DOI: 10.16462/j.cnki.zhjbkz.2017.06.020. Yin YQ, Zhu J, Wu NN, et al. The frequency of drug resistance mutations among different HIV-1 subtypes in Chinese MSM: a Meta-analysis[J]. Chin J Dis Control Prev, 2017, 21(6): 622-626. DOI: 10.16462/j.cnki.zhjbkz.2017.06.020.
[15]	Ndongmo TN, Ndongmo CB, Michelo C. Sexual and reproductive health knowledge and behavior among adolescents living with HIV in Zambia: a case study[J]. Pan Afr Med J, 2017, 26: 71. DOI: 10.11604/pamj.2017.26.71.11312.
[16]	Gregson J, Rhee SY, Datir R, et al. Human immunodeficiency virus-1 viral load is elevated in individuals with reverse-transcriptase mutation M184V/I during virological failure of first-line antiretroviral therapy and is associated with compensatory mutation L74I[J]. J Infect Dis, 2020, 222(7): 1108-1116. DOI: 10.1093/infdis/jiz631.
[17]	Di Vincenzo P, Rusconi S, Adorni F, et al. Prevalence of mutations and determinants of genotypic resistance to etravirine (TMC125) in a large Italian resistance database (ARCA)[J]. HIV Med, 2010, 11(8): 530-534. DOI: 10.1111/j.1468-1293.2009.00819.x.
[18]	李敬云. HIV-1的耐药基因突变[J]. 中国艾滋病性病, 2010, 16(2): 195-197. DOI: 10.13419/j.cnki.aids.2010.02.011. Li JY. HIV-1 drug resistance mutations[J]. Chin J AIDS STD, 2010, 16(2): 195-197. DOI: 10.13419/j.cnki.aids.2010.02.011.
[19]	Gupta RK, Hill A, Sawyer AW, et al. Virological monitoring and resistance to first-line highly active antiretroviral therapy in adults infected with HIV-1 treated under WHO guidelines: a systematic review and meta-analysis[J]. Lancet Infect Dis, 2009, 9(7): 409-417. DOI: 10.1016/S1473-3099(09)70136-7.